Faculty of Medicine
Permanent URI for this communityhttps://repository.ukim.mk/handle/20.500.12188/14
Browse
122 results
Search Results
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, IMPACT OF INITIAL RENAL INVOLVEMENT AND BENCE JONES PROTEINS IN THE URINE ON OVERALL SURVIVAL OF PATIENTS WITH MULTIPLE MYELOMA(Macedonian Association of Anatomists, 2022); ; ; ; Ridova, Nevenka - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Molecular Monitoring in Acute Myeloid Leukemia Patients Undergoing Matched Unrelated Donor - Hematopoietic Stem Cell Transplantation: Single Center Experience(Macedonian Academy of Sciences and Arts/Walter de Gruyter GmbH, 2020-12-08); ; ; Minimal residual disease (MRD) assessment in acute myeloid leukemia (AML) cases is a complex, multi-modality process and, though much of its clinical implications at different points are extensively studied, it remains even now a challenging area. It is a disease the biology of which governs the modality of MRD assessment; in patients harboring specific molecular targets, high sensitivity techniques can be applied. On the other hand, relapse is considered as the leading cause of treatment failure in AML patients undergoing allogeneic hematopoietic stem cell transplantation (alloHSCT). - Some of the metrics are blocked by yourconsent settings
Item type:Publication, HOW WE TREATED ACUTE PROMYELOCYTIC LEUKEMIA: WHERE WE ARE NOW?(Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, 2023); ; ; - Some of the metrics are blocked by yourconsent settings
Item type:Publication, INEFFECTIVE ERYTHROPOIESIS IN PATIENT WITH BETA THALASSEMIA AND MYELODYSPLASTIC SYNDROME CASE REPORT(Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, 2024); ; ; - Some of the metrics are blocked by yourconsent settings
Item type:Publication, DISTINCT SUBGROUP OF PATIENTS WITH UNMUTATED IGHV1-69 CHRONIC LYMPHOCYTIC LEUKEMIA AFFECTED WITH COVID19 INFECTION - SINGLE CENTER EXPERIENCE(Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, 2025); ; ; - Some of the metrics are blocked by yourconsent settings
Item type:Publication, DETECTION OF JAK2 V617F MUTATION IN A PATIENT WITH C-KIT POSITIVE GASTROINTESTINAL STROMAL TUMOR: CASE REPORT(Macedonian Association of Anatomists, 2025-05-02); ; ; ; Popova Labachevska, Marija<jats:p>C-Kit is receptor tyrosine kinase which is involved in various signaling pathways and has been recognized in pathogenesis of several types of cancers including gastrointestinal stromal tumor (GIST). More than 50 years, scientist have been studied GIST and made advances in treatment based on c-Kit inhibition. One of the signaling pathway involving activation via c-Kit is the JAK/STAT pathway located on hematopoietic cells resulting activation of transcription of a variety of genes. Here, we provide a case report of patient with two malignancy c-Kit positive GIST and Essential Thrombocytemia (ET) positive for JAK2 V617F mutation.</jats:p> - Some of the metrics are blocked by yourconsent settings
Item type:Publication, FIRST-LINE IMMUNOCHEMOTHERAPY FOR FOLLICULAR LYMPHOMA PATIENTS- SINGLE CENTER EXPERIENCE(Macedonian Association of Anatomists, 2024); ; ; - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Allogeneic Stem Cell Transplantation in the Treatment for Transfusion-Dependent Thalassemia: Centre Experience(Scientific Foundation Spiroski (publications), 2024-11-30); ; ; BACKGROUND: Allogeneic stem cell transplantation (allo SCT) is still the only curative option for transfusion depended on β-thalassemia major (TDT). In patients with good risk features it is reasonable to anticipate a greater than 90% chance of a successful transplant outcome. With better risk stratification and supportive care, the results of allo-SCT have been improved even in high risk patients who have significant iron overload related organ dysfunction. Choosing the optimal conditioning regimen before allo SCT, stem cell source and focusing on transfusion free survival, as well as graft versus host disease (GVHD) free survival is a challenge in providing the quality of life in the post-transplant period for this indication. The aim of this article is to present first experience in the treatment of TDT with allo SCT from matched related donor (MRD). CASE PRESENTATION: We present a case of male patient diagnosed as thalassemia major (TM) at the age of 15 years referred at University Clinic for pediatric disease in Skopje, Republic of North Macedonia for treatment with allogeneic stem cell transplantation (allo SCT) from matched related family donor (MRD). Patients experienced two allo SCT due to early graft rejection after the first transplantation. The conditioning was done with MAC regimens, busulfan based for the first transplant and treosulfan based for the second transplant. CONCLUSION: Disease severity and the age of the patient has a crucial impact on transplant related mortality (TRM), event free survival (EFS) and the incidence of veno-oclusive liver disease as one of the main complications during SCT. More data is required on the etiology of frequent graft rejection in TDT studying the aspects of the graft and subsequent immune reconstitution that can improve the outcome of allo HSCT for thalassemia major. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Hematologic Autoimmune Manifestation Secondary to Coronavirus Disease 19 Infection – A Single-Center Experience(Scientific Foundation Spiroski (publications), 2021-09-11); ; BACKGROUND: Since December 2019, multiple human cases of novel coronavirus infection were reported, representing with upper respiratory symptoms (influenza-like presentation). The virus was named the severe acute respiratory system coronavirus 2 (SARS-COV-2). Studies have reported cases of patients with coronavirus disease 19 (COVID-19) infection, including development of several autoimmune events that suggest that infection with SARS-CoV-2 may be associated with initiation of autoimmune hematological autoimmune disorders.AIM: This study aims to review the hematological autoimmune phenomena after infection with SARS-CoV-2 to assist into the pathogenic mechanisms, clinical manifestations, and treatment of this group of patients.MATERIALS AND METHODS: This is a retrospective study that includes 21 patients with autoimmune diseases such as secondary immune thrombocytopenia (ITP), autoimmune hemolytic anemia (AIHA), and thrombotic thrombocytopenic purpura (TTP) that have emerged after COVID-19 infection. The patients were diagnosed and treated at the University Clinic of Hematology-Skopje for a period of time from January 2020 to April 2021.RESULTS: The most common hematologic autoimmune disorder was ITP in 13 cases (62%) followed by AIHA in 5 cases (24%) and TTP in 3 individuals (14%). The mean time of onset of the hematologic autoimmune presentations was 18.4 ± 10.3 days. The therapy of this condition in patients with COVID-19 infection requires an individualized approach to achieve a precise balance between the risk of severe bleeding and of thromboembolic events.CONCLUSION: Causal relationship between COVID-19 infection and these autoimmune events still requires further studies. We should all have in mind the risk of development of hematologic autoimmune disorders in infected patiens - Some of the metrics are blocked by yourconsent settings
Item type:Publication, A Rare Case of Superior Ophthalmic Vein Thrombosis and Thrombocytopenia Following ChAdOx1 nCoV-19 Vaccine Against SARS-CoV-2(PAGEPress®, 2021-06); ; ;